Literature DB >> 11001527

Tissue engineering via local gene delivery.

J Bonadio1.   

Abstract

The first goal of this review is to describe a local plasmid gene transfer technology known as the gene activated matrix (GAM). GAM was the first gene therapy designed specifically for tissue engineering applications, and the mechanism of action of plasmid gene transfer is closely tied to the normal sequence of events associated with wound healing. The normal sequence of wound healing events is stereotyped for most tissues, and one assumption has been that GAM could serve as a platform technology for local gene delivery in various tissues and organs. This hypothesis essentially has been proved: animal studies over the past 6 years have established that plasmid genes can be delivered to acutely injured tendon, ligament, bone, muscle, skin, and nerve. The second goal of the review is to describe the most likely "first use" of the technology in man, namely, treatment of osteoporotic hip fracture in the elderly. Although not universally appreciated, interest in osteoporotic fracture should grow because of epidemiological, surgical, and societal considerations. These considerations, plus the unmet clinical need associated with the current standard of fracture care, justify efforts to develop novel therapies for bone regeneration and repair in the elderly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001527     DOI: 10.1007/s001090000118

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  19 in total

1.  Anti-apoptotic therapy with a Tat fusion protein protects against excitotoxic insults in vitro and in vivo.

Authors:  Kevin L Ju; Nathan C Manley; Robert M Sapolsky
Journal:  Exp Neurol       Date:  2007-12-23       Impact factor: 5.330

2.  IN VITRO TRANSPLANTATION OF GENETICALLY MODIFIED CELLS TO THE TENDON SURFACE.

Authors:  Paulus J J Couvreur; Chunfeng Zhao; Stephen Murphy; Peter C Amadio
Journal:  J Musculoskelet Res       Date:  2008

Review 3.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

4.  The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation.

Authors:  Themis R Kyriakides; Matt J Foster; Grant E Keeney; Annabel Tsai; Cecilia M Giachelli; Ian Clark-Lewis; Barrett J Rollins; Paul Bornstein
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

5.  Cell-based therapies for regenerating bone.

Authors:  S B Goodman
Journal:  Minerva Ortop Traumatol       Date:  2013-04-01

6.  Regulated non-viral gene delivery from coaxial electrospun fiber mesh scaffolds.

Authors:  Anita Saraf; L Scott Baggett; Robert M Raphael; F Kurtis Kasper; Antonios G Mikos
Journal:  J Control Release       Date:  2009-12-16       Impact factor: 9.776

7.  The noninvasive, quantitative, in vivo assessment of adenoviral-mediated gene delivery in skin wound biomaterials.

Authors:  Carrie Y Peterson; Ashkaun Shaterian; Alexandra K Borboa; Ana M Gonzalez; Bruce M Potenza; Raul Coimbra; Brian P Eliceiri; Andrew Baird
Journal:  Biomaterials       Date:  2009-09-24       Impact factor: 12.479

8.  Adenoviral vector tethering to metal surfaces via hydrolyzable cross-linkers for the modulation of vector release and transduction.

Authors:  Ilia Fishbein; Scott P Forbes; Michael Chorny; Jeanne M Connolly; Richard F Adamo; Ricardo A Corrales; Ivan S Alferiev; Robert J Levy
Journal:  Biomaterials       Date:  2013-06-15       Impact factor: 12.479

Review 9.  Local strategies to prevent and treat osteoporosis.

Authors:  F Brennan Torstrick; Robert E Guldberg
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

10.  Efficacy and mechanism of poloxamine-assisted polyplex transfection.

Authors:  Jeremy Zhang; Sooneon Bae; Jeoung Soo Lee; Ken Webb
Journal:  J Gene Med       Date:  2013 Aug-Sep       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.